The physicians looked at several clinical trials to create evidence-based guidelines. They found a loading phase of three monthly injections of ranibizumab 0.5 mg, an anti-angiogenic that has been approved to treat ARMD, provided the best improvement in visual acuity. They also found starting treatment within two weeks of diagnosis provided the best outcome, and waiting more than one month to start treatment led to further vision loss.
Related Articles on Ophthalmology:
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions
Vision Treatment Company AcuFocus Raises $65M in Funding
Cataract Surgery Gains Popularity as Surgical Option for Glaucoma
